Effect of postmenopausal hormone replacement therapy on climacteric syndrome, body weight and blood pressure;Postmenopausale Hormonsubstitution und ihre Auswirkungen auf das Beschwerdebild des klimakterischen Syndroms, auf Gewicht und Blutdruck

Zentralblatt fur Gynakologie

Volumn 119, Issue 3, 1997, Pages 128-132

  Fritsch, H ^a,d   Fritsch, W ^b   Julius, U ^c   Rehak, E ^d   Wieczorek, A ^a   Hanefeld, M ^c  

^a Frauenklinik ^*  (Germany)

^b Neurologische Klinik Kreiskrankenhaus Freiberg gGmbH   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Kali Chemie Pharma GmbH   (Germany)

Author keywords

body weight; climacteric syndrome; hormone replacement therapy; hypertension; postmenopause

Indexed keywords

CONJUGATED ESTROGEN; MEDROGESTONE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION;

BLOOD PRESSURE; BODY WEIGHT; CLIMACTERIC; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030892920     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Barrett-Connor E, Wingard DL, Criqui MH: Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA 261 (1989) 2095-2100
2. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265 (1991) 1861-1867
3. Blum M, Zacharowitsch D, Pery J, Gilerowitch M: Estrogen replacement therapy (ERT) by a special regimen in the years following menopause. Clin Exp Obstet Gynecol 16 (1989) 9-11
4. Christiansen C, Riis BJ: Five years with continuous combined oestrogen[progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern. Brit J Obstet Gynaecol 97 (1990) 1087-1092
5. Elias AN, Meshkinpour H, Valenta LJ: Attenuation of hypertension by conjugated estrogens. Ann Clin Res 38 (1982) 15-19
6. Göretzlehner G, Lauritzen C: Praktische Hormontherapie in der Gynäkologie. Berlin - New York: Walter de Gruyter 1992
7. Haenggi W, Birkhaeuser MH: A new peroral estrogen[progestin combination for postmenopausal hormonal substitution: An open multricentric field study, Maturitas 16 (1993) 111-122
8. Julius U, Fritsch H, Fritsch W, Rehak E, Fücker K, Leonhardt W, Hanefeld M: Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women. Clin Invest 72 (1994) 502-507
9. [9J Justus B: Epidemiologie und Therapie des Klimakterischen Syndroms. Medicamentum 31 (1990) 151-155
10. Kaplan MN: Estrogen replacement therapy. Effect on blood pressure and other cardiovascular risk factors. J Reprod Med 30 (1985) 802-804
11. Kritz-Silverstein D, Barrett-Connor E: Long-term Postmenopausal Hormone Use, Obesity, and Fat Distibution in Older Women. JAMA 275 (1996) 46-49
12. Kuhl H: Hormonale Kontrazeption und Substitutionstherapie: Die Bedeutung des Gestagens für kardiovaskuläre Erkrankungen. Geburtshilfe Frauenheilkd 52 (1992) 653-662
13. Kühl H: Substitutionstherapie mit Östrogenen und Gestagenen. 11. Arbeitstreffen des Züricher Gesprächskreises. Dtsch Ärztebl 91 (1994) B571-B573
14. LaRosa JC: Management of postmenopausal women who have hyperlipidemia. Am J Med 96 (1994) 19S-24S
15. Law MR, Wald NJ, Meade TW: Strategies for prevention of osteoporosis and hip fracture. Brit Med J 303 (1991) 453-459
16. Lip GY, Beevers M, Churchill D, Beevers DG: Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 8 (1994) 491-494
17. Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ: Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein(a). J Lab Clin Med 123 (1994) 837-841
18. Paterion MEL, Wade-Evans T, Sturdee DW, Thom MH, Studd JWW: Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Brit Med J 248 (1980) 822-824
19. Pfeffer RI: Estrogen use, hypertension and stroke in postmenopausat women. J Chron Dis 31 (1978) 389
20. Proudler AJ, Ahmed AIH, Crook D, Fogelman I, Rymer JM, Stevenson JC: Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 346 (1995) 89-90
21. Regensteiner JG, William RH, Byyny RL, Pickett CW, Woodard WD, Moore LG: Short-term effects of estrogen and progestin on blood pressure of normotensive postmenopausal women. J Clin Pharmacol 31 (1991) 543-548
22. Riedel M, Rafflenbeul W: Östrogene und kardiovaskuläre Erkrankungen in der Postmenopause. Dtsch Med Wochenschr 117 (1992) 1205-1211
23. Seed M: Sex hormones, lipoproteins, and cardiovascular risk. Atherosclerosis 90 (1991) 1-7
24. Sonnendecker EW, Polakow ES, Benade AJ, Simchowitz E: Serum lipoproteins effects of conjugated estrogen and a sequential conjugated estrogen-medrogeston regimen in hysterectomized postmenopausal women. Am J Obstet Gynecol 160 (1989) 1128-1134
25. Strecker IR: Physiologische Abläufe im Klimakterium. In: Wolf AS, Schneider HPG (Hrsg.) Östrogene in Diagnostik und Therapie. Berlin - Heidelberg - New York: Springer 1990, 67-76
26. Teichmann AT, Wieland H, Cremer P, Hinney B, Kuhn W, Seidel D: Auswirkungen von Medrogeston und konjugierten Östrogenen auf Serumlipid- und Lipoprotein-Konzentrationen. Maturitas 7 (1985) 343-350.
27. The writing group for the PEPI trial: Effects of estrogen or estrogen[progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen[progestin interventions (PEPI) trial. JAMA 273 (1994) 199-208
28. Wenderlein JM: Postmenopausale Haut- und Schleimhautprobleme - Durch Östrogensubstitution vermeidbar? Dtsch Ärztebl 89 (1992) B726-B727